SeaCrest Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

SeaCrest Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-68	Closed	-$40K	–	1306
2022 Q2	$40K	Buy	+68	New	+$44.2K	0.01%	1217
2020 Q4	–	Sell	-567	Closed	-$317K	–	645
2020 Q3	$317K	Buy	567 +112	+25%	+$67.9K	0.05%	372
2020 Q2	$284K	Buy	+455	New	+$258K	0.05%	405
2019 Q2	–	Sell	-58	Closed	-$24K	–	1552
2019 Q1	$24K	Sell	58 -14	-19%	-$5.76K	﹤0.01%	1218
2018 Q4	$27K	Sell	72 -19	-21%	-$6.95K	0.01%	1119
2018 Q3	$37K	Sell	91 -10	-10%	-$3.81K	0.01%	1125
2018 Q2	$35K	Buy	101 +12	+13%	+$3.75K	0.01%	1129
2018 Q1	$31K	Buy	89 +12	+16%	+$4.17K	0.01%	1161
2017 Q4	$29K	Buy	+77	New	+$31.2K	0.01%	1194

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

SeaCrest Wealth Management's REGN Position: Q3 2022 in Review

SeaCrest Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2022, closing a stake of 68 shares — an estimated $40K sold.

SeaCrest Wealth Management first reported a position in REGN in Q4 2017 and held it in 9 quarters. The position peaked at $317K in Q3 2020. 1,080 funds tracked by Wall St. Rank hold REGN as of Q3 2022.

SeaCrest Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
SeaCrest Wealth Management sold 68 Regeneron Pharmaceuticals shares in Q3 2022, an estimated $40K.
SeaCrest Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2017 and held it in 9 quarters.
SeaCrest Wealth Management's Regeneron Pharmaceuticals position peaked at $317K in Q3 2020.
1,080 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2022.

Based on SeaCrest Wealth Management's 13F filing for Q3 2022, filed 15 Nov 2022.